Low Hb levels at admission associated with higher CV and all cause mortality

New investigation revealed that lower levels of hemoglobin at admission are associated with higher cardiovascular, all-cause mortality, and major ischemic events among elderly patients with the acute coronary syndrome who are managed invasively. The study was published in the "International Journal of Cardiology", 2022. 

Hemoglobin (Hb) levels have popped up as a useful tool for risk stratification and the prediction of outcomes after myocardial infarction in patients with cardiovascular issues admitted to a hospital. To understand this, researchers conducted a trial to evaluate the prognostic impact of hemoglobin on elderly patients, where the larger prevalence of anemia and the higher rate of comorbidities could directly impact cardiovascular risk. 

Subjects from the ELDERLY-2 trial were included in this analysis. They were stratified according to the values of hemoglobin at admission. Cardiovascular mortality within one year was the primary endpoint of measurement. All-cause mortality, MI, Bleeding Academic Research Consortium (BARC) type 2–3 or 5 bleeding, any stroke, re-hospitalization for a cardiovascular event or stent thrombosis (probable or definite) within 12 months after index admission were the secondary endpoints of measurement.